11:04 AM EST, 12/17/2024 (MT Newswires) -- BioVaxys Technology ( BVAXF ) said Tuesday it secured a 48-kilogram supply of GMP-grade lipid to produce its DPX antigen packaging delivery platform.

The company's DPX technology is a patented delivery platform that can package and deliver a range of bioactive molecules to produce targeted, long-lasting immune responses. The DPX platform facilitates immune cell recruitment and antigen uptake at the injection site for delivery to regional lymph nodes, stimulating a robust and durable antigen-specific immune response.

"We were able to acquire the lipids on commercially attractive terms, with 48 kg of lipid anticipated to cover production for any conceivable preclinical or clinical trials over the next several years and save the company over one year in manufacturing lead time for this drug substance," said Kenneth Kovan, President & Chief Operating Officer of BioVaxys ( BVAXF ).

The company's shares were last seen up $0.005 to $0.055 on the Canadian Securities Exchange.